Three Steps to Interpret Clinical Trials

Slides:



Advertisements
Similar presentations
Appraisal of an RCT using a critical appraisal checklist
Advertisements

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Teaching the Art of Literature Analysis
1 Health and Disease in Populations 2002 Week 9 – 2/5/02 Randomised controlled trials 2 Dr Jenny Kurinczuk.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
ARISTOTLE TTR Subanalysis
Study by: Granger et al. NEJM, September 2011,Vol No. 11 Presented by: Amelia Crawford PA-S2 Apixaban versus Warfarin in Patients with Atrial Fibrillation.
CRITICAL APPRAISAL Dr. Cristina Ana Stoian Resident Journal Club
Critical Appraisal of an Article on Therapy. Why critical appraisal? Why therapy?
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
Cohort Studies Hanna E. Bloomfield, MD, MPH Professor of Medicine Associate Chief of Staff, Research Minneapolis VA Medical Center.
Critical Appraisal of an Article on Therapy (2). Formulate Clinical Question Patient/ population Intervention Comparison Outcome (s) Women with IBS Alosetron.
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
VBWG OASIS-5 The Fifth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Critiquing for Evidence-based Practice: Therapy or Prevention M8120 Columbia University Suzanne Bakken, RN, DNSc.
How to Analyze Therapy in the Medical Literature (part 2)
1 HISTORY OF "CLINICAL TRIALS“ - 1, 1794 Treatment of yellow fever by bleeding, RUSH, 1794 “ I began to extract a small amount of blood each time. The.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
EBCP. Random vs Systemic error Random error: errors in measurement that lead to measured values being inconsistent when repeated measures are taken. Ie:
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Critical Appraisal Did the study address a clearly focused question? Did the study address a clearly focused question? Was the assignment of patients.
Jim Hoehns, Pharm.D.. Lancet 2013;382: Albers G et al. Chest. 2001; 119 (suppl): 300S. Ischemic stroke 85% Hemorrhagic stroke 15% Other 5% Cryptogenic.
Vorapaxar for Secondary Prevention in Patients with Prior Myocardial Infarction Benjamin M. Scirica, MD, MPH On behalf of the TRA 2°P-TIMI 50 Steering.
LIPID: Long-term Intervention with Pravastatin in Ischemic Disease Purpose To determine whether pravastatin will reduce coronary mortality and morbidity.
BIOE 301 Lecture Seventeen. Progression of Heart Disease High Blood Pressure High Cholesterol Levels Atherosclerosis Ischemia Heart Attack Heart Failure.
Naotsugu Oyama, MD, PhD, MBA A Trial of PLATelet inhibition and Patient Outcomes.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
PRODIGY Objective Study Design Primary Composite Endpoint
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Vanderbilt Sports Medicine Evidence-Base Medicine How to Practice and Teach EBM Chapter 5 : Therapy.
Hypothesis: baseline risk status of the patients and proximity to a recent cardiovascular event influence the response to dual anti-platelet therapy. Patients.
VBWG OASIS-6 The Sixth Organization to Assess Strategies in Acute Ischemic Syndromes trial.
Baseline Characteristics of the Patients* - Part I The ONTARGET Investigators. N Engl J Med 2008 [Epub on Mar 31]
بسم الله الرحمن الرحیم.
Critical Appraisal Course for Emergency Medicine Trainees Module 3 Evaluation of a therapy.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2013.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Ryan Sparks, PharmD, BCPS PGY2 Cardiology Resident
Nephrology Journal Club The SPRINT Trial Parker Gregg
Trials Adrian Boyle.
Bedside monitoring to adjust antiplatelet therapy for Coronary stenting N Engl J Med Nov 29;367: Prof. Soo-Joong Kim / R3 Yu Ho Lee.
CLINICAL PROTOCOL DEVELOPMENT
Confidence Intervals and p-values
Alcohol, Other Drugs, and Health: Current Evidence
HOPE: Heart Outcomes Prevention Evaluation study
SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.
AIM HIGH Niacin plus Statin to prevent vascular events
Critical Reading of Clinical Study Results
NAPLEX preparation: Biostatistics
Updates in Anticoagulation: What Did We Learn From ESC 2017?
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
New Strategies to Prevent CV Events After Hospital Discharge
PAD Patients vs Post-ACS Patients:
Disclosures. Evaluating Recent Clinical Trial Data in the Secondary Prevention of ACS.
CRASH 2 Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2):
Clarifying Optimal Patient Selection for Long-Term DAPT Post-MI
The Hypertension in the Very Elderly Trial (HYVET)
1 Information Mastery Skills Calculating RR, RRR, ARR and NNTs A. Bornstein, MD, FACC Assistant Professor of Medicine Weil Cornell Medical College New.
ASPIRE CLASS 6: Interpreting Results and Writing an Abstract
Appraisal of an RCT using a critical appraisal checklist
Apixaban vs VKA and Aspirin vs Placebo in Patients with Atrial Fibrillation and ACS/PCI: The AUGUSTUS Trial Renato D. Lopes, MD, PhD on behalf of the.
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Primary safety endpoint
Level of Evidence Lecture 4.
Medical Statistics Exam Technique and Coaching, Part 2 Richard Kay Statistical Consultant RK Statistics Ltd 22/09/2019.
Yoga treatment for chronic non-specific low back pain
Presentation transcript:

Three Steps to Interpret Clinical Trials Mark C. Granberry, Pharm.D. Professor and Vice Chair of Pharmacy Practice UAMS College of Pharmacy

Learning objectives   At the end of this presentation, you should be able to: 1. Evaluate the validity of a clinical drug trial 2. Assess efficacy, safety, and effectiveness outcomes of a study 3. Objectively interpret clinical trial results

Three Questions must be answered: 1. What is the probability that the results of this trial are true? 2. To whom do the results apply? 3. Assuming the results are likely to be true, will you now have to change the way you do things?

First Question: Do you think it’s true Good study design Clearly defined criteria Focus on primary endpoint! How well the study is conducted?

The Perfectly Designed Study Two or more groups, identical in every respect at the beginning One, and only one thing is changed If the groups are different at the end, there could only be two causes The intervention Play of chance

Getting Groups the Same at the Beginning Randomization Avoiding pitfalls of randomization Intention-to-treat analysis Check Baseline Characteristics

Baseline Characteristics Are groups similar? N Engl J Med 2014; 371:993-1004

Change Only One Thing: The Intervention Being Studied Blinding Unblinded Single blind Double Blind Why So Important? How do you know if blinding was effective?

Question Two: To Whom Do the Results Apply? Inclusion Criteria Exclusion Criteria

Question Two: To Whom Do the Results Apply? Underrepresented Groups

The Third Question: Based on this new information – Will you now have to change the way you do things? Are the results CLINICALLY significant? Do the benefits outweigh the risks?

It’s a Little Like Gambling in Las Vegas Probability of Truth Benefit versus Risk

Assessing Benefit and Risk Number Needed to Treat (Benefit) Number Needed to Harm (Risk) The number of individuals who must be treated for a period of time so that one additional individual will avoid/have event.

Example Exercise NNT of 5, treatment for 1 month, avoid 1 additional death NNT of 100, treatment for 5 years, avoid 1 additional hospitalization

Compare Benefit to Risks NNT = 5 for 1 month to prevent 1 additional death NNH =20 for 1 month to cause 1 additional major bleeding event Do the benefits outweigh the risk?

Endpoints Survival Quality of Life Validated QoL questionnaires Hospitalizations Disability Assessments (Modified Rankins Scale for Stroke) Surrogate Endpoints Blood Pressure A1C

Composite Endpoints Fourrier N Engl J Med 2017;376:1713-22

Trials with No Benefit Same size calculation EUCLID N Engl J Med 2017;376:32-40

Summary